Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.

Antonio AscioneMassimo De LucaMario MelazziniSimona MontillaMaria Paola TrottaSalvatore PettaMassimo PuotiVincenzo SangiovanniVincenzo MessinaSavino BrunoAntonio IzziErica VillaAlessio AghemoAnna Linda ZignegoAlessandra OrlandiniLuca FontanellaAntonio GasbarriniMarco MarzioniEdoardo G GianniniAntonio Craxìnull null

Published in: Infection (2018)

Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65.

Keyphrases

hepatitis c virus
end stage renal disease
human immunodeficiency virus
newly diagnosed
peritoneal dialysis
patient reported outcomes
antiretroviral therapy